Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
17 December 2020
Health sciences
The more than 100 medical students who graduated virtually from the University of the Free State (UFS) Faculty of Health Sciences on Monday (14 December), graduated with a pass rate of 98% in a tumultuous year dominated by the COVID-19 pandemic. The MB ChB class of 2020 – a total of 104 students from the School of Clinical Medicine – graduated virtually on Monday due to COVID-19.

The more than 100 medical students who graduated virtually from the University of the Free State (UFS) Faculty of Health Sciences on Monday (14 December), graduated with a pass rate of 98% in a tumultuous year dominated by the COVID-19 pandemic.

The MB ChB class of 2020 – a total of 104 students from the School of Clinical Medicine – graduated virtually on 14 December due to COVID-19. Another virtual graduation is scheduled for 4 January 2021.

An uncomfortable reality
Dr Lynette van der Merwe, undergraduate medical programme director in the School of Clinical Medicine at the UFS, congratulated the latest UFS doctors on their success. Said Dr Van der Merwe: “In a tumultuous year dominated by the COVID-19 pandemic, this group of final-year medical students refused to give in to the pressure and disruption of national lockdown, emergency remote teaching, an adjusted academic calendar, and frontline exposure as healthcare professionals in training.”  

“They persevered against all odds, faced up to an uncomfortable reality, and showed remarkable resilience.”

According to Dr Van der Merwe, the class of 2020 completed the gruelling five-year medical programme with a pass rate of 98,3%, impressing external examiners who commented on their respectful attitude towards patients and thorough knowledge and skill.  

“The School of Clinical Medicine and Faculty of Health Sciences are immensely proud of our new colleagues and look forward to their contribution to the future of healthcare in South Africa. This achievement would not have been possible without the unwavering commitment of the academic and support staff who guided our students and led the way for them to achieve a life-long dream.”  

“We look back with gratitude on a year that required more than the usual amount of adaptability, creativity, innovation, faith, patience, bravery, and endurance.  It is these qualities that set apart the doctors who graduate from the UFS, and those who train them,” says Dr Van der Merwe.

Hope for the future
She says while COVID-19 is still a harsh reality and the future holds much uncertainty, 2020 has shown that there is hope when we face challenges with grace under pressure, and a firm belief in our goals and values. “Class of 2020, may you continue to rise above fear, chaos and disappointment, may you take heart and walk your journey with strength, may you bring healing to our people and lead us well.”

Drs Kaamilah Joosub and Lynette Upman, who also graduated on Monday, were awarded the prestigious Bongani Mayosi Medical Students Academic Prize – a national award which aims to recognise final-year medical students who epitomise the academic, legendary, and altruistic life of the late Prof Mayosi. The awards are presented to final-year MB ChB students from all South African medical faculties. This is the first year it has been awarded.

View the virtual graduation

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept